Cetera Investment Advisers Has $8.88 Million Stock Holdings in GSK plc (NYSE:GSK)

Cetera Investment Advisers trimmed its stake in GSK plc (NYSE:GSK - Free Report) by 3.6% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 262,599 shares of the pharmaceutical company's stock after selling 9,739 shares during the period. Cetera Investment Advisers' holdings in GSK were worth $8,881,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Dorsey & Whitney Trust CO LLC lifted its stake in GSK by 2.5% during the fourth quarter. Dorsey & Whitney Trust CO LLC now owns 11,506 shares of the pharmaceutical company's stock worth $389,000 after purchasing an additional 278 shares during the last quarter. GC Wealth Management RIA LLC lifted its position in shares of GSK by 2.6% in the 4th quarter. GC Wealth Management RIA LLC now owns 14,009 shares of the pharmaceutical company's stock worth $474,000 after buying an additional 353 shares during the last quarter. Jacobi Capital Management LLC lifted its position in shares of GSK by 3.9% in the 4th quarter. Jacobi Capital Management LLC now owns 10,403 shares of the pharmaceutical company's stock worth $352,000 after buying an additional 389 shares during the last quarter. Gladstone Institutional Advisory LLC boosted its holdings in shares of GSK by 3.4% in the 4th quarter. Gladstone Institutional Advisory LLC now owns 12,221 shares of the pharmaceutical company's stock valued at $413,000 after buying an additional 407 shares during the period. Finally, CENTRAL TRUST Co raised its stake in GSK by 5.6% during the fourth quarter. CENTRAL TRUST Co now owns 7,756 shares of the pharmaceutical company's stock worth $262,000 after acquiring an additional 414 shares during the period. 15.74% of the stock is currently owned by institutional investors and hedge funds.

GSK Price Performance

GSK stock traded up $1.32 on Thursday, hitting $37.54. 7,527,723 shares of the company's stock traded hands, compared to its average volume of 4,825,151. GSK plc has a 1-year low of $31.72 and a 1-year high of $45.93. The stock has a market cap of $77.45 billion, a price-to-earnings ratio of 23.61, a P/E/G ratio of 1.12 and a beta of 0.51. The stock has a fifty day moving average of $37.48 and a 200-day moving average of $35.98. The company has a current ratio of 0.78, a quick ratio of 0.52 and a debt-to-equity ratio of 1.12.

GSK (NYSE:GSK - Get Free Report) last announced its earnings results on Wednesday, April 30th. The pharmaceutical company reported $1.13 EPS for the quarter, beating the consensus estimate of $1.08 by $0.05. The business had revenue of $10.06 billion during the quarter, compared to the consensus estimate of $7.52 billion. GSK had a return on equity of 48.59% and a net margin of 8.13%. GSK's revenue was up 2.1% compared to the same quarter last year. During the same period in the prior year, the business posted $0.43 earnings per share. On average, analysts forecast that GSK plc will post 4.14 EPS for the current fiscal year.

GSK Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, July 10th. Stockholders of record on Friday, May 16th will be given a $0.4216 dividend. This is an increase from GSK's previous quarterly dividend of $0.39. This represents a $1.69 annualized dividend and a dividend yield of 4.49%. The ex-dividend date of this dividend is Friday, May 16th. GSK's dividend payout ratio (DPR) is 86.60%.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on GSK shares. StockNews.com upgraded GSK from a "buy" rating to a "strong-buy" rating in a research report on Thursday, April 24th. BNP Paribas assumed coverage on shares of GSK in a research report on Tuesday, April 15th. They set a "neutral" rating and a $35.25 price target for the company. Morgan Stanley started coverage on GSK in a research note on Wednesday, February 12th. They issued an "equal weight" rating for the company. Finally, Hsbc Global Res upgraded shares of GSK to a "strong sell" rating in a research report on Monday, April 28th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating and four have issued a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $40.58.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.